Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).
Notice with comment period.
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Study to Explore Early Development (SEED) Phase 3. This study evaluates potential risk factors for Autism Spectrum Disorders (ASD) and the behavioral and health characteristics of children with autism by conducting a case control study to compare them with children who have other developmental disabilities and children from the general population.
CDC must receive written comments on or before July 23, 2019.
You may submit comments, identified by Docket No. CDC-2019-0036 by any of the following methods:
Federal eRulemaking Portal:
Regulations.gov. Follow the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Lead, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to Regulations.gov.
Please note: Submit all comments through the Federal eRulemaking portal ( regulations.gov ) or by U.S. mail to the address listed above.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
To request more information on the proposed project or to obtain a contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: firstname.lastname@example.org.
End Further Info
Start Supplemental Information
Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;Start Printed Page 24145
2. Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to be collected; and
4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.
5. Assess information collection costs.
Study to Explore Early Development (SEED) Phase 3—Extension—National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Autism spectrum disorders (ASD) are group of neurodevelopmental disorders characterized by qualitative impairments in social interaction, and communication and stereotyped behaviors and interests. Recent systematic population surveys and routine monitoring systems in the U.S. and other countries indicate the prevalence to be 1-2%. Apart from the identification of some rare genetic conditions that are commonly associated with autism, causal mechanisms for the disorder remain largely unknown.
The Children's Health Act of 2000 mandated CDC to establish autism surveillance and research programs to address the number, incidence, and causes of autism and related developmental disabilities. Under the provisions of this act, NCBDDD funded five Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) through program announcements in FY2001 and FY2002; CDC's NCBDDD served as the sixth CADDRE site.
For the first funding cycle (2001- 2006), each CADDRE grantee had three core objectives: To develop a protocol for a multi-site collaborative epidemiologic study focused on autism (which was eventually named the Study to Explore Early Development [SEED]); to conduct surveillance of autism and other developmental disabilities; and to conduct site-specific investigator initiated studies on autism. In FY 2006, through a second CADDRE funding cycle, five grantees were awarded. The CADDRE activities for the second funding cycle (2006-2011) were limited to implementation of the first phase of SEED (subsequently known as SEED 1). CDC served as the sixth CADDRE SEED 1 site during this period. A second phase of SEED (SEED 2) was funded under a third funding cycle (2011- 2016). Five CADDRE grantees received the awards. Again, CDC served as the sixth SEED 2 site.
A third phase of SEED (SEED 3) was funded in July 2016. Five extramural sites were funded. Together with the CDC, they are implementing the SEED 3 collaborative protocol. The SEED 3 protocol for identification of study participants, recruitment, and study data collection flow is similar to the protocols for SEED 1 and 2. CDC obtained approval to collect information for SEED 3 in 2017 (OMB 0920-1171). The current request is to obtain an extension of this approval so that data collection may continue beyond the current expiration date of 3/31/2020.
While all SEED phases have the same research goals and the same basic study design, data collection was greatly streamlined and revised between SEED 1, SEED 2, and SEED 3. Many study instruments and data collection components included in the SEED 1 protocol are not included in the SEED 3 protocol; two instruments included in the SEED 3 protocol were developed subsequent to SEED 1 to capture an abbreviated version of information that had been included on some of the discontinued SEED 1 forms and to capture some additional information overlooked in the SEED 1 protocol; and instruments included in all phases of SEED underwent review and minor revision subsequent to SEED 1 to address ambiguities and difficulties experienced during SEED 1 data collection. No additional changes are requested from the SEED 3 protocol that initially obtained OMB approval. Implementing this phase of SEED will increase the total SEED pooled sample size for investigation of high priority hypotheses. Maintaining the same basic study design and general protocol integrity will ensure that data pooling can be achieved across SEED phases.
Families will be identified from each of the three groups: Autism Spectrum Disorder (ASD), other developmental delay or disorder comparison group (DD), and a second comparison group of children randomly drawn from the entire study cohort population (POP). It is expected that the six SEED 3 study sites will enroll a total of 2,106 children and complete the study protocol. The data collection will take approximately nine hours 10 minutes (ASD group); five hours 30 minutes (POP group); two hours 45 minutes (DD group) to complete, which includes: (1) Maternal telephone interview with questions about maternal reproductive history and pregnancy with the index child, (2) parent-completed questionnaires about parental and child health and child development, (3) in-person child developmental evaluation, (4) maternal and child anthropometry measurements, and (5) biosampling from biological parents and child. There are no costs to participants other than their time. The total estimated annual burden hours are 7,118.
Estimated Annualized Burden Hours
|Type of respondents||Form name||Number of respondents||Number of responses per
respondent||Average burden per
(in hours)||Total burden (in hours)|
|Mother, ASD workflow. All potential participants sent mailing||Invitation Packet/Response Card||1,718||1||10/60||286|
|Mother, ASD workflow. Potentially eligible with contact by study staff||Invitation Call Script and Social Communication Questionnaire||859||1||30/60||430|
|Mother, ASD workflow. Eligible, consented, and enrolled; assigned to the ASD workflow based on enrollment intake||Enrollment Packet||469||1||20/60||156|
|Mother, ASD workflow. Completed this study step||Follow-up Phone Call Script and Checklist and Pregnancy Reference Form||422||1||15/60||106|
|Start Printed Page 24146|
|Mother, ASD workflow. Completed this study step||Maternal Interview Call||422||1||1||422|
|Mother, ASD workflow. Completed this study step||Self-Administered Forms||375||1||105/60||656|
|Mother, ASD workflow. Completed this study step||Follow-up Call 2||375||1||20/60||125|
|Mother, ASD workflow. Completed this study step||Clinic/Home Visit—Developmental Assessment, saliva collection, overall consent||328||1||225/60||1,230|
|Father, ASD workflow. Completed this study step||Clinic/Home Visit—Saliva Collection||164||1||15/60||41|
|Child, ASD workflow. Completed this study step||Clinic/Home Visit—Developmental Assessment||328||1||135/60||738|
|Mother, POP workflow. All potential participants sent mailing||Invitation Packet/Response Card||1,466||1||10/60||244|
|Mother , POP workflow. Potentially eligible with contact by study staff||Invitation Call Script and Social Communication Questionnaire||733||1||30/60||367|
|Mother , POP workflow. Eligible, consented, and enrolled; assigned to the POP workflow based on enrollment intake||Enrollment Packet||334||1||20/60||111|
|Mother, POP workflow. Completed this study step||Follow-up Phone Call Script and Checklist and Pregnancy Reference Form||301||1||15/60||75|
|Mother, POP workflow. Completed this study step||Maternal Interview Call||301||1||1||301|
|Mother, POP workflow. Completed this study step||Self-Administered Forms||267||1||105/60||467|
|Mother, POP workflow. Completed this study step||Follow-up Call 2||267||1||20/60||89|
|Mother, POP workflow. Completed this study step||Developmental Assessment, saliva collection, overall consent||234||1||50/60||195|
|Father, POP workflow. Completed this study step||Clinic/Home Visit—Saliva Collection||117||1||15/60||29|
|Child, POP workflow. Completed this study step||Clinic/Home Visit—Developmental Assessment, saliva collection||234||1||90/60||351|
|Mother, DD workflow. All potential participants sent mailing||Invitation Packet/Response Card||641||1||10/60||107|
|Mother, DD workflow. Potentially eligible with contact by study staff||Invitation Call Script and SCQ||321||1||30/60||161|
|Mother, DD workflow. Eligible, consented, and enrolled; assigned to the DD workflow based on enrollment intake||Enrollment Packet||175||1||20/60||58|
|Mother, DD workflow. Completed this study step||Follow-up Phone Call Script, and Checklist and Pregnancy Reference Form||158||1||15/60||40|
|Mother, DD workflow. Completed this study step||Maternal Interview Call||158||1||1||158|
|Mother, DD workflow. Completed this study step||Self-Administered Forms||140||1||55/60||128|
|Mother, DD workflow. Completed this study step||Follow-up Call 2||140||1||20/60||47|
End Supplemental Information
Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.
[FR Doc. 2019-10839 Filed 5-23-19; 8:45 am]
BILLING CODE 4163-18-P